期刊文献+

噻托溴铵对慢性阻塞性肺疾病大鼠血清及肺组织中肺表面活性蛋白-D的影响

Effects of tiotropium bromide on pulmonary surfactant protein D in serum and lung tissue of chronic obstructive pulmonary disease rats
原文传递
导出
摘要 目的通过研究噻托溴铵对慢性阻塞性肺疾病(COPD)大鼠血清及肺组织中肺表面活性蛋白-D(pulmonary surfaetant proteinD,SP—D)水平的影响,探讨噻托溴铵治疗COPD的新机制。方法采用烟熏加气管内注入内毒素法建立大鼠COPD模型。将雄性SD大鼠随机分为对照组、COPD组和噻托溴铵干预组,每组10只。HE染色观察大鼠肺、支气管的病理改变,测定肺平均内衬间隔及平均肺泡数。酶联免疫吸附试验检测各组大鼠血清中SP—D的含量。Westernblot及免疫组织化学方法检测大鼠肺组织中SPD的含量变化。结果COPD组大鼠肺、支气管的HE染色符合COPD的病理改变;COPD组大鼠出现明显肺气肿,噻托溴铵组也出现肺气肿,但程度较轻。COPD组大鼠血清及肺组织中SP—D水平较对照组均明显升高(P〈0.01),噻托溴铵丁预组与COPD组相比血清及肺组织中SP—D水平均显著降低(P〈0.01),但仍明显高于对照组(P〈0.01)。结论噻托溴铵可以降低COPD大鼠血清及肺组织中SP—D水平.这一作用可能是通过减轻气道炎症及肺气肿的程度来实现的。 Objective To investigate ~he new mechanism of tiotropium bromide in the treatment of chronic obstructive puhnonary disease (COPD) by studying its effect on pulmonary surfaetant protein D (SP-D) in serum and lung tissue of COPD rats. Methods We established the rat COPD models by passive smoking as well as intratracheal instillation of I.ipopolysaceharide respectively. Thirty male SD rats were randomly divided into the control group, the COPD group and the tiotropium bromide treatment group (n = 10). The pathologic change of the lung tissue and airway were observed by HE staining. The level of SP I) in serum was measured by enzyme-linked immunosorbent assay. The level of SP-D in lung tissue was detected by western blot and immunohistochemistry. Results HE staining proved that the rat COPD models were successfully established. The COPD group appears obvious emphysema, while the treatment group appears mild emphysema. The expression of SP-D in serum and lung tissue of the COPD group were obviously stronger than that in the control group ( P 〈0. 01). The level of SP-D in serum and lung tissue of the treatment group was between the control group' s and the COPD group' s. Conclusions Tiotropium bromide could reduce the level of SP-D in serum and lung tissue of COPD rat. These effects may be exerted through alleviating airway inflammation and the degree of emphysema.
出处 《国际呼吸杂志》 2013年第3期180-184,共5页 International Journal of Respiration
关键词 慢性阻塞性肺疾病 噻托溴铵 肺表面活性蛋白-D Chronic obstructive puhnonary disease Tiotropium bromide Pulmonary surfactant protein 1)
  • 相关文献

参考文献19

  • 1Duvoix A,Miranda E,Perez J. Evaluation of fulllength,cleaved and nitrosylated serum surfactant protein D as biomarkers for COPD[J].COPD,2011.79-95. 被引量:1
  • 2Winkler C,Atochina-Vasserman EN,Holz O. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD[J].Respiratory Research,2011.29. 被引量:1
  • 3Shakoori TA,Sin DD,Ghafoor F. Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease[J].Disease Markers,2009,(6):287-294. 被引量:1
  • 4Sin DD,Leung R,Gan WQ. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD:a pilot study[J].BMC Pulmonary Medicine,2007.13. 被引量:1
  • 5李红梅,崔德健,佟欣,庞宝森,高亚兵,王德文.熏香烟加气管注内毒素和单纯熏香烟法建立大鼠COPD模型[J].中国病理生理杂志,2002,18(7):808-812. 被引量:105
  • 6管小俊,宋琳,郭雪君,徐卫国.肺内输入骨髓间充质干细胞对肺气肿大鼠慢性炎症的调控[J].中国呼吸与危重监护杂志,2011,10(6):520-526. 被引量:9
  • 7Vincken W,van Noord JA,Greefhorst AP. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium[J].European Respiratory Journal,2002.209-216. 被引量:1
  • 8van Noord JA,Bantje TA,Eland ME. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease.The Dutch Tiotropium Study Group[J].Thorax,2000.289-294. 被引量:1
  • 9Anzueto A,Tashkin D,Menjoge S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium[J].Pulmonary Pharmacology and Therapeutics,2005.75-81. 被引量:1
  • 10García Ruiz AJ,Leiva Fernández F,Martos Crespo F. Cost effectiveness analysis of tiotropium compared to ipratropium and salmeterol[J].Archivos De Bronconeumologia,2005.242-248. 被引量:1

二级参考文献61

  • 1张永,程德云,王慧,苏巧俐,陈小菊,关键.慢性阻塞性肺疾病大鼠肺内白细胞介素-8和肿瘤坏死因子-α与气道炎症的关系研究[J].中国呼吸与危重监护杂志,2003,2(6):355-359. 被引量:41
  • 2张弛,林如平,刘洪,陈云凤.鱼腥草注射液对慢性阻塞性肺疾病患者炎症细胞因子与肺功能的影响[J].中国中医药科技,2006,13(5):294-295. 被引量:18
  • 3Matthlesen S, Bahulayan A, Kempkens S, et al. Musearinic receptors mediate stimulation of humanlung fibroblast proliferation. Am J Respir Cell Mol Biol, 2006,35 : 621-627. 被引量:1
  • 4Haag S, Matthiesen S, Juergens UR, et al, Muscarinie receptors mediate stimulation of collagen synthesis in human lung fibroblasts. Eur Respir J, 2008,31 : 15. 被引量:1
  • 5Gosen R, Sophie I, Bos T, et al. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med, 2005, 171: 1096-1102. 被引量:1
  • 6Cecramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term funetional impacts of tiotropium in COPD: the UPLIFT trial. COPD, 2004,1 : 303- 312. 被引量:1
  • 7Caramori G,Adcoek I. Pharmacology of airway inflammation in asthma and COPD. Pulm Pharmacol Ther, 2003,16: 247- 277. 被引量:1
  • 8Clsse B. Antimuscarinic treatment for lung diseases from research to clinical praetice. Life Sci,2001,68:2557-2564. 被引量:1
  • 9Woolhouse IS, Bayley DI, Stockley RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antirtypsin deficiency and the role of leukotriene B4. Thorax,2002,57:709-714. 被引量:1
  • 10Perng DW, Huang HY, Chen HM, et al. Characteristic of airway inflammation and bronchodilator reversibility in COPD:a potential guide to treatment. Chest, 2004,126: 375- 381. 被引量:1

共引文献127

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部